Is Instil Bio, Inc. (TIL) Halal?

NASDAQ Healthcare United States $53M
✗ NOT HALAL
Confidence: 83/100
Instil Bio, Inc. (TIL) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 144.4% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Instil Bio, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 144.4%
/ 30%
188.4%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 144.4%
/ 33%
188.4%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 33.0%
/ 33%
43.0%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 144.4%
/ 33%
188.4%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 33.0%
/ 33%
43.0%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-10.70
P/B Ratio
0.4
EV/EBITDA
-1.1
EV: $62M
Revenue
$0
Beta
2.1
High volatility
Current Ratio
34.5

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -50.6%
Return on Assets (ROA) -14.9%

Cash Flow & Balance Sheet

Operating Cash Flow-$56M
Free Cash Flow-$66M
Total Debt$87M
Debt-to-Equity70.5
Current Ratio34.5
Total Assets$264M

Price & Trading

Last Close$8.36
50-Day MA$8.10
200-Day MA$17.13
Avg Volume125K
Beta2.1
52-Week Range
$5.67
$42.79

About Instil Bio, Inc. (TIL)

CEO
Mr. Bronson Crouch
Employees
14
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$53M
Currency
USD

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Instil Bio, Inc. (TIL) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Instil Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Instil Bio, Inc.'s debt ratio?

Instil Bio, Inc.'s debt ratio is 144.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 33.0%.

What are Instil Bio, Inc.'s key financial metrics?

Instil Bio, Inc. has a market capitalization of $53M. Return on equity stands at -50.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.